Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be BioNTech's financial performance in Q1 2025 post-settlement?
Revenue increase over 10% • 25%
Revenue decrease over 10% • 25%
Profit increase over 10% • 25%
Profit decrease over 10% • 25%
BioNTech's Q1 2025 financial report
BioNTech Settles COVID-19 Vaccine Royalties, Paying $791.5M to NIH and $467M to UPenn
Dec 27, 2024, 02:00 PM
BioNTech has reached two separate settlement agreements concerning royalty payments related to its COVID-19 vaccine. The company will pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of Pennsylvania. These agreements were confirmed by BioNTech in recent filings. The settlements address disputes over whether royalties were owed based on the locations where the licensed products were manufactured and sold. Despite these settlements, BioNTech will retain license rights under certain patents held by the University of Pennsylvania.
View original story
$2.86 - $2.90 • 25%
$2.91 - $2.95 • 25%
$2.96 - $3.00 • 25%
$2.80 - $2.85 • 25%
No significant change • 25%
Increase up to 5% • 25%
Increase over 5% • 25%
Decrease • 25%
Profit increase • 25%
Loss increase • 25%
Loss reduction • 25%
Profit decrease • 25%
Moderate Increase • 25%
Significant Increase • 25%
Decrease • 25%
No Change • 25%
Below 3.0x • 25%
3.0x - 3.25x • 25%
3.26x - 3.5x • 25%
Above 3.5x • 25%
10% - 12% • 25%
13% - 15% • 25%
16% - 18% • 25%
Above 18% • 25%
Break-even • 25%
Loss less than €50 million • 25%
Profitable • 25%
Loss more than €50 million • 25%
Increase • 25%
Uncertain/Other • 25%
No significant change • 25%
Decrease • 25%
Less than $500 million • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
No • 50%
Yes • 50%
Investment in new vaccine technology • 25%
Expansion of vaccine production • 25%
No significant strategic move • 25%
New partnership in vaccine development • 25%